Biotech is cool! We just made huge progress in treating liver scarring/cirrhosis caused by being fat. And no, Ozempic can't treat this!
Reposted from
Adam Feuerstein✡️
To put these new $AKRO data into context, patients w/ cirrhosis due to MASH have a severe form of disease w/ few treatment options outside of liver transplant.
Once MASH progresses to cirrhosis, median survival is about 5 years, three times shorter than for patients with moderate MASH.
Once MASH progresses to cirrhosis, median survival is about 5 years, three times shorter than for patients with moderate MASH.
Comments